The Sato Lab (Kei Sato) Profile picture
Nov 4 7 tweets 3 min read Twitter logo Read on Twitter
BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 BA.2.86 (aka #Pirola).
*BA.2.86 is has >30 mutations in the genome.
Please RT🔥 1/
biorxiv.org/content/10.110…

Image
Image
Epidemic dynamics modeling by @jampei2 and @JarelElgin showed that the relative effective reproduction number (Re) of BA.2.86 is 1.07-fold higher than that of the currently predominant EG.5.1, suggesting that BA.2.86 has the potential to become the next predominant one. 2/ Image
Growth assay showed that the replication capacity of BA.2.86 is similar to or lower than that of BA.2, its parental strain. BA.2.86 is less replicative than EG.5.1 at the cell culture level. 3/ Image
Four antivirals, molnupiravir (EIDD-1931), nirmatrelvir, remdesivir and ensitrelvir were all effective against BA.2.86. 4/ Image
A cell-based fusion assay showed that the fusogenicity of BA.2.86 spike is a bit (1.5-fold) greater than that of the parental BA.2 spike. 5/ Image
Infection experiments in hamsters showed that both the intrinsic pathogenicity and replication kinetics of BA.2.86 are significantly lower than those of the parental BA.2. 6/ Image
Overall, BA.2.86 does not appear to pose an increased risk to human society. However, it is possible that its virological phenotype may change or even worsen in the future by acquiring additional mutations. Continued monitoring and surveillance are important now and then. 7/7

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with The Sato Lab (Kei Sato)

The Sato Lab (Kei Sato) Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @SystemsVirology

Sep 19
BREAKING🔔 The 28th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant under monitoring, BA.2.86 (aka #Pirola). Please retweet/repost🔥 1/
thelancet.com/journals/lanin…
Here I summarized the mutations detected in BA.2.86. 2/ Image
1⃣Transmissibility/fitness (Re):
Analysis by Jumpei @jampei2 using the data from 🇩🇰 showed that BA.2.86's Re is greater than XBB.1.5 and comparable to or even greater than EG.5.1. 3/ Image
Read 8 tweets
Sep 12
BREAKING🔔 The 27th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant of interest, EG.5 (aka #Eris) Please RT🔥 1/
thelancet.com/journals/lanin…
Currently, a subvariant of XBB.1.9, EG.5 (aka XBB.1.9.2.5) is well documented in Twitter (maybe aka #X) and elsewhere. 2/
* EG.5.1 S = XBB.1.9.2 S + #Q52H + #F456L
* XBB.1.9.2 S = XBB.1.5 S.

Image
On August 9, #WHO has classified EG.5 as a ‘variant of interest’. 3/
who.int/docs/default-s…
Read 11 tweets
Sep 7
BREAKING🔔 A new study from G2P-Japan🇯🇵 is out! The preprint will be out so soon, but first we show our results on BA.2.86 - transmissibility, infectivity and immune resistance. This would be the 4th non-peer-reviewed🗒, but includes some new stuff. Please retweet/repost🔥 1/
Cf. Non-peer-reviewed works on BA.2.86:
The 1st🗒 from @yunlong_cao :


The 2nd🗒 from @BenjMurrell :


The 3rd🗒 from @BarouchLab :


Here I summarized the mutations detected in BA.2.86. 2/


Image
1⃣Transmissibility/fitness (Re):
Analysis by Jumpei @jampei2 using the data from 🇩🇰 showed that BA.2.86's Re is greater than XBB.1.5 and comparable to or even greater than EG.5.1. 3/ Image
Read 9 tweets
Aug 9
BREAKING🔔 A new preprint from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We evaluated the antiviral humoral immunity induced by breakthrough infection (BTI) of XBB subvariants and its effect against a new one, EG.5. Please RT. 1/
biorxiv.org/content/10.110…
Currently, a subvariant of XBB.1.9, EG.5 (aka XBB.1.9.2.5) is well documented in Twitter (maybe aka #X) and elsewhere.
EG.5.1 S = XBB.1.9.2 S + Q52H + F456L, and XBB.1.9.2 S = XBB.1.5 S. 2/
https://t.co/Tm6soayTIV
Image
On July 19, #WHO has classified EG.5 as a ‘variant under monitoring’. 3/
Read 11 tweets
Aug 9
#拡散希望 速報🔔 G2P-Japan🇯🇵の新しいプレプリント「XBB亜系統のブレイクスルー感染で惹起される液性免疫とEG.5」を、bioRxiv @biorxivpreprint に発表しました。本研究は、最近増加傾向にある新しい変異株EG.5と、XBBブレイクスルー感染の関係を検討しました。1/
biorxiv.org/content/10.110…
最近、XBB.1.9の亜系統「EG.5(XBB.1.9.2.5)」の感染拡大が、国内外(やツイッター)で話題になっています。特にEG.5.1は、XBB.1.9.2(スパイクはXBB.1.5と同じ)のスパイクに、Q52HとF456Lというふたつの変異が追加されたものです。2/
https://t.co/0muHApwNVb
Image
EG.5は、東京都感染症対策センター(東京iCDC)の情報でも、割合の増加が報告されています。このような国内外の状況を受け、#WHO は7月19日に、この株を‘variant under monitoring’に分類しています。3/
Read 11 tweets
Aug 5
ここのところいろいろなところでツイートされてよく見かけるこの論文(の解説和訳)に関連して、基礎ウイルス学的観点(と、これまでのG2P-Japan🇯🇵の研究成果)から、新型コロナのこれまでの進化の変遷について簡単にちょっとまとめてみようと思います🎐1/
rplroseus.hatenablog.com/entry/2023/05/…
2021年末のオミクロンBA.1、その直後の2022年初頭のBA.2、そして2022年夏のBA.5までは、出現から全世界規模での流行まで、「全とっかえ」状態でした。つまり、「最強ががすべてを制する」という構図が繰り返されました。これはオミクロン以前の、アルファ、デルタでも同じ構図でした。2/
この構図があやふやになってきたのが、2022年下半期です。BA.2.75の出現を挟み、BQ系統とXBB系統の台頭とそれらの多様化、そして、それらのさまざまな系統でR346T, K444T, N460K変異などの共通の変異が獲得されるという「収斂進化イベント」が起こりました。3/
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(